NovMetaPharma Co (XKRX:229500) Total Liabilities : ₩2,891.94 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is NovMetaPharma Co Total Liabilities?

NovMetaPharma Co's Total Liabilities for the quarter that ended in Dec. 2024 was ₩2,891.94 Mil.

NovMetaPharma Co's quarterly Total Liabilities declined from Dec. 2022 (₩7,979.83 Mil) to Dec. 2023 (₩3,713.55 Mil) and declined from Dec. 2023 (₩3,713.55 Mil) to Dec. 2024 (₩2,891.94 Mil).

NovMetaPharma Co's annual Total Liabilities declined from Dec. 2022 (₩7,979.83 Mil) to Dec. 2023 (₩3,713.55 Mil) and declined from Dec. 2023 (₩3,713.55 Mil) to Dec. 2024 (₩2,891.94 Mil).

NovMetaPharma Co Total Liabilities Historical Data

The historical data trend for NovMetaPharma Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovMetaPharma Co Total Liabilities Chart

NovMetaPharma Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

1,502.74

8,810.81

7,979.83

3,713.55

2,891.94

NovMetaPharma Co Semi-Annual Data
	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24
Total Liabilities	Get a 7-Day Free Trial					1,502.74	8,810.81	7,979.83	3,713.55	2,891.94

NovMetaPharma Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

NovMetaPharma Co's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2672.421	+	(139.883	+	31.139
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	34.496	+	14)
	=	2,891.94

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	4648.527	-	1756.588
	=	2,891.94

NovMetaPharma Co's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2672.421	+	(139.883	+	31.139
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	34.496	+	14)
	=	2,891.94

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	4648.527	-	1756.588
	=	2,891.94

NovMetaPharma Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of NovMetaPharma Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

NovMetaPharma Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » NovMetaPharma Co Ltd (XKRX:229500) » Definitions » Total Liabilities

Traded in Other Exchanges

N/A

Address

727 13, Gangnam-gu, Seoul eonju layer, Seoul, KOR

Website

http://www.novmeta.com

NovMetaPharma Co Ltd researches and develops new medicines and health supplements for metabolic diseases. The company is developing a therapeutic agent that is in Phase 2a clinical trial for Type 2 diabetes and obesity. It also develops therapeutic agents for Alzheimer's disease, immune system diseases, osteoporosis, and non-alcoholic fatty liver diseases.

NovMetaPharma Co Headlines

No Headlines